Created as part of the OHSU Knight Cancer Institute, the Immune Monitoring & Cancer Omics Laboratory (IMCO) provides seamless support and comprehensive analytics for clinical and translational studies. The primary objective of the IMCO platform is to offer clients a broad suite of state-of-the-art research and CLIA assays that generate high-quality data to inform and improve novel standards for patient care.
We provide an end-to-end process that includes sample acquisition, preparation, assay execution, and data generation. All of our offerings—including research assays—are performed using rigorously standardized procedures and are internally validated to ensure accuracy, reproducibility, and consistency.
The IMCO comprehensively characterizes immune responses to determine mechanisms of resistance and develop biomarkers to predict therapeutic outcomes or toxicities. Our program is designed is to work closely with individual partners to deliver the services needed for each specific study.
IMCO Panel of Scientific Advisors:
